Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date

References

• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61. doi:10.1182/blood-2015-08-604520
   PubMed Web of Science ®Google Scholar
• Fernandez H, Sun Z, Yao X, et al. Anthracycline dose intensification in Acute myeloid leukemia. N Engl J Med. 2009;361(13):1249–1259. doi:10.1056/NEJMoa0904544
   PubMed Web of Science ®Google Scholar
• Luskin MR, Lee J-W, Fernandez HF, et al. High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: updated analyses from eastern cooperative oncology trial E1900. Blood. 2014;124(21):373. doi:10.1182/blood.V124.21.373.373
   Web of Science ®Google Scholar
• Lee J, Joo Y, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118(14):3832–3841. doi:10.1182/blood-2011-06-361410
   PubMed Web of Science ®Google Scholar
• Alibhai S, Leach M, Minden M, Brandwein J. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer. 2009;115(13):2903–2911. doi:10.1002/cncr.24373
   PubMed Web of Science ®Google Scholar
• Key statistics for acute myeloid leukemia (AML). Atlanta: American Cancer Society; 2022. Available from: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html. Accessed May 20, 2022.
   Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975–2018. Bethesda; 2021. Available from: https://seer.cancer.gov/csr/1975_2018/. Accessed May 20, 2022.
   Google Scholar
• Recher C, Rollig C, Berard E, et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2021;36(4):913–922. doi:10.1038/s41375-021-01425-9
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87. doi:10.1016/j.blre.2019.04.005
   PubMed Web of Science ®Google Scholar
• Klepin H, Estey E, Kadia T. More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate. Am Soc Clin Oncol Edu Book. 2019;39:421–432. doi:10.1200/EDBK_239097
   PubMedGoogle Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924. doi:10.3324/haematol.2012.066100
   PubMed Web of Science ®Google Scholar
• Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31:43–62. doi:10.1016/j.blre.2016.09.005
   PubMed Web of Science ®Google Scholar
• Heuser M, Smith BD, Fiedler W, et al. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021;100(5):1181–1194. doi:10.1007/s00277-021-04465-4
   PubMed Web of Science ®Google Scholar
• Cortes J, Heidel F, Hellman A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–389. doi:10.1038/s41375-018-0312-9
   PubMed Web of Science ®Google Scholar
• Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nat Med. 1980;287:795–801.
   Google Scholar
• Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol. 2012;180(1):2–11. doi:10.1016/j.ajpath.2011.09.009
   PubMed Web of Science ®Google Scholar
• Lainez-Gonzalez D, Serrano-Lopez J, Alonso-Dominguez JM. Understanding the hedgehog signaling pathway in acute myeloid leukemia stem cells: a necessary step toward a cure. Biology. 2021;10(4). doi:10.3390/biology10040255
   PubMed Web of Science ®Google Scholar
• Tibes R, Al-Kali A, Oliver GR, et al. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. J Hematol Oncol. 2015;8:114. doi:10.1186/s13045-015-0211-8
   PubMed Web of Science ®Google Scholar
• Tibes R, Mesa RA. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol. 2014;7(18). doi:10.1186/1756-8722-7-18
   PubMed Web of Science ®Google Scholar
• Terao T, Minami Y. Targeting Hedgehog (Hh) pathway for the Acute myeloid leukemia treatment. Cells. 2019;8(4):312. doi:10.3390/cells8040312
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Bigner SH, Bigner DD, et al. Identification of an amplified, highly expressed gene in a human glioma. Science. 1987;236(4797):70–73. doi:10.1126/science.3563490
   PubMed Web of Science ®Google Scholar
• Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841–851. doi:10.1016/S0092-8674(00)81268-4
   PubMed Web of Science ®Google Scholar
• Bai LY, Chiu CF, Lin CW, et al. Differential expression of sonic hedgehog and Gli1 in hematological malignancies. Leukemia. 2008;22:226–228. doi:10.1038/sj.leu.2404978
   PubMed Web of Science ®Google Scholar
• Kobune M, Iyama S, Kikuchi S, et al. Stromal cells expressing hedgehog-interacting protein regulate the proliferation of myeloid neoplasms. Blood Cancer J. 2012;2:e87.
   PubMed Web of Science ®Google Scholar
• Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood. 2012;119(10):2196–2204. doi:10.1182/blood-2011-10-383752
   PubMed Web of Science ®Google Scholar
• O’Brien C, Kreso A, Jamieson C. Cancer stem cells and self-renewal. Clin Cancer Res. 2010;16(12):3113–3120. doi:10.1158/1078-0432.CCR-09-2824
   PubMed Web of Science ®Google Scholar
• Beachy P, Karhadkar S, Berman D. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432(7015):324–331. doi:10.1038/nature03100
   PubMed Web of Science ®Google Scholar
• Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature. 2000;406:1005–1009. doi:10.1038/35023008
   PubMed Web of Science ®Google Scholar
• Minami Y, Fukushima N, Sadarangani A, Hironobu M, Jamieson C, Naoe T. Abstract 1884: treatment with Hedgehog inhibitor PF-913 attenuates leukemia-initiation potential in acute myeloid leukemia cells. Cancer Res. 2014;74:1884.
   Web of Science ®Google Scholar
• Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107(10):1422–1429. doi:10.1111/cas.13019
   PubMed Web of Science ®Google Scholar
• Munchhof MJ, Li Q, Shavnya A, et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett. 2012;3(2):106–111. doi:10.1021/ml2002423
   PubMed Web of Science ®Google Scholar
• Martinelli G, Oehler VG, Papayannidis C, et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015;2(8):e339–e346. doi:10.1016/S2352-3026(15)00096-4
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Fiedler W, et al. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020;13(1):92. doi:10.1186/s13045-020-00929-8
   PubMed Web of Science ®Google Scholar
• Daurismo (glasdegib) [package insert]. New York, NY: Pfizer; 2018.
   Google Scholar
• Hoy SM. Glasdegib: first global approval. Drugs. 2019;79(2):207–213. doi:10.1007/s40265-018-1047-7
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with.30% blasts. Blood. 2015;126(3):291–299. doi:10.1182/blood-2015-01-621664
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556–561. doi:10.1200/JCO.2009.23.9178
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677. doi:10.1200/JCO.2011.38.9429
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma. 2012;53(1):110–117. doi:10.3109/10428194.2011.606382
   PubMed Web of Science ®Google Scholar
• Zhang Y, Asghari HH, Chan O, et al. Hypomethylating agent and venetoclax combination therapy yields superior outcomes when compared to hypomethylating agent monotherapy in patients ≥70 years with acute myeloid leukemia. Blood. 2019;134:1368. doi:10.1182/blood-2019-127772
   PubMed Web of Science ®Google Scholar
• Tremblay G, Westley T, Cappalleri JC, et al. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons. Clinicoecon Outcomes Res. 2019;11:551–565. doi:10.2147/CEOR.S203482
   PubMed Web of Science ®Google Scholar
• van Beekhuizen S, Hu Y, Gezin A, et al. The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. J Clin Oncol. 2020;38:e19512–e19512. doi:10.1200/JCO.2020.38.15_suppl.e19512
   Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208–217. doi:10.1002/ajh.26039
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas B, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Chaudhry P, Singh M, Triche TJ, Guzman M, Merchant AA. GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML. Blood. 2017;129(26):3465–3475. doi:10.1182/blood-2016-05-718585
   PubMed Web of Science ®Google Scholar
• Zeidan A, Schuster M, Joris M, et al. Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): effects on marrow recovery and transfusion Independence. J Clin Oncol. 2020;38:7526. doi:10.1200/JCO.2020.38.15_suppl.7526
   Web of Science ®Google Scholar
• Sekeres MA, Schuster M, Joris M, et al. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Ann Hematol. 2022. doi:10.1007/s00277-022-04853-4
   PubMed Web of Science ®Google Scholar
• Shallis R, Podoltsev NA, Prebet T, et al. Trial in Progress: glad-AML - a randomized, Phase 2 trial of glasdegib with two standard decitabine regimens for older patients with newly-diagnosed, poor-risk acute myeloid leukemia. Blood. 2020;136:29. doi:10.1182/blood-2020-139428
   Web of Science ®Google Scholar
• Cortes JE, Douglas Smith BD, Wang ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol. 2018;93(11):1301–1310. doi:10.1002/ajh.25238
   PubMed Web of Science ®Google Scholar
• Cortes J, Dombret H, Merchant A, et al. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncolo. 2019;15(31):3531–3545.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216–228. doi:10.1016/S1470-2045(18)30010-X
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, Version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721–749. doi:10.6004/jnccn.2019.0028
   PubMed Web of Science ®Google Scholar